Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells

[1]  P. Ji,et al.  Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain. , 2011, Bioorganic & medicinal chemistry letters.

[2]  P. R. Deepa,et al.  Clinico-pathological correlations of fatty acid synthase expression in retinoblastoma: an Indian cohort study. , 2011, Experimental and molecular pathology.

[3]  Suranjana Das,et al.  Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing , 2010, PloS one.

[4]  P. R. Deepa,et al.  Evaluation of suitable solvents for testing the anti-proliferative activity of triclosan - a hydrophobic drug in cell culture. , 2010, Indian journal of biochemistry & biophysics.

[5]  Armin Ruf,et al.  Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design. , 2010, Journal of molecular biology.

[6]  Pascal Benkert,et al.  QMEAN server for protein model quality estimation , 2009, Nucleic Acids Res..

[7]  Site Li,et al.  Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies. , 2009, Bioorganic & medicinal chemistry.

[8]  Timm Maier,et al.  The Crystal Structure of a Mammalian Fatty Acid Synthase , 2008, Science.

[9]  E. Gabrielson,et al.  Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment , 2007, Clinical Cancer Research.

[10]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[11]  Y. Wong,et al.  Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  H. Kubinyi.  Hydrogen Bonding: The Last Mystery in Drug Design? , 2007 .

[13]  Michael Levitt,et al.  Near-native structure refinement using in vacuo energy minimization , 2007, Proceedings of the National Academy of Sciences.

[14]  Gerd Folkers,et al.  Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies , 2006 .

[15]  J. Menéndez,et al.  Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Ram Samudrala,et al.  Prediction of HIV-1 Protease Inhibitor Resistance using a Protein–Inhibitor Flexible Docking Approach , 2005, Antiviral therapy.

[17]  J. Menéndez,et al.  Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. , 2004, Archivum immunologiae et therapiae experimentalis.

[18]  M. C. Archer,et al.  Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. , 2004, Carcinogenesis.

[19]  Jeffrey W. Smith,et al.  Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.

[20]  F. Camassei,et al.  Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. , 2003, Investigative ophthalmology & visual science.

[21]  S. Peikin,et al.  Orlistat: its current status as an anti-obesity drug. , 2002, European journal of pharmacology.

[22]  V. Anderson,et al.  Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells , 2002, Cancer Chemotherapy and Pharmacology.

[23]  F. Kuhajda,et al.  Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. , 2001, Biochemical and biophysical research communications.

[24]  F. Kuhajda.  Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. , 2000, Nutrition.

[25]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[26]  H. Kubinyi.  Structure-based design of enzyme inhibitors and receptor ligands. , 1998, Current opinion in drug discovery & development.

[27]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[28]  L. Jacobs,et al.  Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Kridel,et al.  Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat , 2007, Nature Structural &Molecular Biology.

[30]  Robert K. Murray,et al.  Harper's Illustrated Biochemistry , 2003 .

[31]  A. Sali,et al.  Modeller: generation and refinement of homology-based protein structure models. , 2003, Methods in enzymology.

[32]  C. Townsend,et al.  Synthesis and antitumor activity of an inhibitor of fatty acid synthase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. M. Carey,et al.  Fatty acid synthase from rabbit mammary gland. , 1975, Methods in enzymology.